IP Library Granted Patent US 9,012,373
Granted Patent B2
US 9,012,373 · App. 13/566,806 · Granted Apr 21, 2015

Systems and methods for processing fluids

Inventors: T. Christian Boles (Bedford, MA); Ezra Solomon Abrams (Newton, MA)
Assignee: Sage Science, Inc.
C12N15/1003B01L3/502715B01L3/502776C12N15/102C40B50/06C12M45/09C12P19/34B01L3/502753B01L3/502761B01L2400/086B01L2200/0652B01L2300/0819
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,012,373
App. No.
13/566,806
Granted
Apr 21, 2015
Kind
B2
Abstract

Systems and methods for processing fluid samples are disclosed. Fluid sample processing is accomplished using a series of microfluidic bump arrays include an automated and integrated system for sorting particles from a biological sample, lysing those particles to expose total RNA or DNA, purifying the RNA or DNA, processing the RNA or DNA by chemical or enzymatic modification, to select RNA or DNA molecules by size, or to generate, optionally, a sequencing library. The sequencing library is suitable for use in next generation sequencing (“NGS”).

Claims (24)

1. A system for processing of a biological fluid, comprising:

at least one input reservoir for receiving a biological fluid and separating one or more cells therefrom;

at least one bump array mechanism configured with a plurality of treatment areas including at least:

a first treatment area configured with a first buffer, and

a second treatment area configured with a transposase complex having at least one sequencing adaptor;

and

at least one output reservoir, wherein

the first treatment area is configured to generate a purified deoxyribonucleic acid (“DNA”) from the one or more cells upon the one or more cells traversing the first treatment area,

the second treatment area is configured to receive the purified DNA and combine the purified DNA with a transposase complex having at least one sequencing adaptor to produce a second solution, and

the at least one output reservoir is configured to receive at least the second solution.

2. The system according to claim 1 , wherein the biological fluid includes at least one of the following: whole blood, urine, spinal fluid, saliva, buccal swabs, sputum, bronchial lavage, gastric lavage fluid, microbial culture media, feces, buffy coat, serum, plasma, platelet concentrate, water samples, and/or any other biological, chemical, and/or biochemical fluids and/or any combination thereof.

3. The system according to claim 1 , wherein the at least one bump array uses a deterministic lateral displacement to process at least one of the purified DNA and the second solution.

4. The system according to claim 1 , further comprising a sequential arrangement of a plurality of bump arrays to process at least one of the purified DNA and the second solution.

5. The system according to claim 1 , wherein the biological fluid is whole blood.

6. The system according to claim 1 , wherein the at least one output reservoir fractionates the output solutions based on a size of at least one cell contained within the output solution.

7. The system of claim 1 , wherein the at least one input reservoir comprises a plurality of input reservoirs.

8. The system of claim 7 , wherein the plurality of input reservoirs comprise a first reservoir having at least the biological fluid, a second reservoir having the first buffer, and a third reservoir having the transposase complex having the at least one sequencing adaptor.

9. The system of claim 8 , further comprising a plurality of input ports configured to direct the contents of respective reservoirs into the at least one bump array.

10. The system of claim 1 , further comprising a particle trap.

11. The system of claim 10 , wherein the at least one bump array is configured with the particle trap.

12. The system of claim 1 , wherein the first buffer comprises a cell lysis buffer.

13. The system of claim 1 , wherein the plurality of treatment areas further comprise at least one of: a third treatment area configured with a wash buffer and a fourth treatment area configured with a guanidine isothiocyanate (GuSCN) buffer.

14. The system of claim 13 , wherein the wash buffer comprises a nuclear wash buffer.

15. The system of claim 13 , wherein the GuSCN buffer is configured to dissociate nuclei and remove nuclear proteins from DNA.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2015
From: ABRAMS, EZRA SOLOMON
To: SAGE SCIENCE, INC.
Reel/Frame 034997/0137 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2012
From: BOLES, T. CHRISTIAN
To: SAGE SCIENCE, INC.
Reel/Frame 029445/0989 →
Continuity (2)
Provisional Application 61515063 · Aug 4, 2011
Related Publication 20130079251A1 · Mar 28, 2013